COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI HC QHC Q BHBH CICI BLBL COCO BUBU More..
Tweet (RCT)0.62[0.18-2.09]recoveryRRCIRegeneron (RCT)0.29[0.17-0.48]death/hosp.Tau​2 = 0.07; I​2 = 23.4%Early treatment0.34[0.18-0.65]66% improvementRegeneron (RCT)0.06[0.00-1.10]symp. caseRRCITau​2 = 0.00; I​2 = 0.0%PrEP0.06[0.00-1.10]94% improvementRegeneron (DB RCT)0.11[0.01-2.06]hosp./ERRRCITau​2 = 0.00; I​2 = 0.0%PEP0.11[0.01-2.06]89% improvementAll studies0.30[0.19-0.48]70% improvement4 casirivimab/imdevimab COVID-19 4/15/21Tau​2 = 0.00; I​2 = 0.0%; Z = 5.05 (p < 0.0001)Lower RiskIncreased Risk
Casirivimab/imdevimab (REGN-COV2) is an artificial "antibody cocktail" designed to produce resistance to the SARS-CoV-2 coronavirus. It consists of a mixture of two monoclonal antibodies. The combination of antibodies is intended to prevent mutational escape. Submit updates/corrections below.
PEP Regeneron Press Release (Preprint) hosp./ER, ↓88.9%, p=0.06 Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of REGEN-COV™ (casirivimab and imdevimab)
Press release for a phase 3 prophylaxis trial reporting lower hospitalization/ER and symptomatic cases, and faster recovery with 1,200mg subcutaneous casirivimab with imdevimab.
Early Regeneron Press Release (Preprint) hosp./death, ↓71.3%, p<0.0001 New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
Press release for new phase III data showing lower hospitalization/mortality, and faster symptom resolution among the subset of patients with at least one risk factor. Some variants may escape antibodies [1].
PrEP Regeneron Press Release (Preprint) symp. case, ↓93.6%, p=0.009 Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
Interim results of REGEN-COV prophylaxis showing 100% prevention of symptomatic infection (8/223 placebo vs. 0/186 REGEN-COV), and approximately 50% lower overall rates of infection (symptomatic and asymptomatic) (23/223 placebo vs. 10/18..
Early Regeneron Press Release (Preprint) recov. time, ↓38.0%, p=0.22 Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients
Analysis of the first 275 patients in a trial of the REGN-COV2 antibody cocktail showing reductions in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. Greatest improvements were seen with patients..
In Vitro Baum et al., Science, 21 Aug 2020, 369:6506, 1014-1018, doi:10.1126/science.abd0831 (Peer Reviewed) (In Vitro) in vitro Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
In Vitro study showing that, under pressure from individual antibodies, mutant viruses were rapidly selected that evaded the blocking function of all individual antibodies tested, including antibodies that potently bind to highly-conserve..
N/A Hansen et al., Science, 21 Aug 2020, 369:6506, 1010-1014, doi:10.1126/science.abd0827 (Peer Reviewed) animal study Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Study using humanized mice and blood samples from recovered COVID-19 patients to generate antibodies targeting multiple different regions of the critical receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The spike protein on ..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.